Literature DB >> 29557539

Birmingham vasculitis activity and chest manifestation at diagnosis can predict hospitalised infection in ANCA-associated vasculitis.

Juyoung Yoo1, Seung Min Jung1, Jason Jungsik Song1, Yong-Beom Park1,2, Sang-Won Lee3,4.   

Abstract

We investigated the development rate and time, risk factors, predictors, and aetiologies of hospitalised infection in Korean patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). We retrospectively reviewed the medical records of 154 patients with AAV. Hospitalised infection was considered only when patients were admitted for serious infection related to AAV or AAV treatment. The gap-time was defined as the period from diagnosis to the first hospitalised infection or to the last visit for uninfected patients. We calculated Birmingham vasculitis activity score (BVAS) or BVAS for granulomatosis with polyangiitis (GPA) and five factor score (FFS (2009)) and reviewed medications administered. We set the optimal cut-offs of BVAS and that of FFS (2009) at diagnosis at 20.5 and 1.5. Forty-four patients (28.6%) were admitted for serious infection. One-, 5- and 10-year hospitalised infection free survival rates were 85.1, 77.9 and 72.7%, respectively. In multivariable logistic regression analysis of significant variables in comparison analysis, only chest manifestation at diagnosis (OR 2.692) was remarkably associated with hospitalised infection. In multivariable Cox hazard model analysis of significant variables in Kaplan-Meier analysis, BVAS at diagnosis ≥ 20.5 (HR 2.375) and chest manifestation at diagnosis (HR 2.422) were independent predictors of hospitalised infection during the gap-time. Bacterial pneumonia was the most common infectious aetiology (N = 29), followed by fungal infection including aspergillosis (N = 6). BVAS and chest manifestation at diagnosis can predict hospitalised infection during the gap-time.

Entities:  

Keywords:  ANCA-associated vasculitis; Aetiology; Hospitalised infection; Predictors; Risk factors

Mesh:

Substances:

Year:  2018        PMID: 29557539     DOI: 10.1007/s10067-018-4067-5

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  27 in total

1.  A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS).

Authors:  J H Stone; G S Hoffman; P A Merkel; Y I Min; M L Uhlfelder; D B Hellmann; U Specks; N B Allen; J C Davis; R F Spiera; L H Calabrese; F M Wigley; N Maiden; R M Valente; J L Niles; K H Fye; J W McCune; E W St Clair; R A Luqmani
Journal:  Arthritis Rheum       Date:  2001-04

2.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Authors:  John H Stone; Peter A Merkel; Robert Spiera; Philip Seo; Carol A Langford; Gary S Hoffman; Cees G M Kallenberg; E William St Clair; Anthony Turkiewicz; Nadia K Tchao; Lisa Webber; Linna Ding; Lourdes P Sejismundo; Kathleen Mieras; David Weitzenkamp; David Ikle; Vicki Seyfert-Margolis; Mark Mueller; Paul Brunetta; Nancy B Allen; Fernando C Fervenza; Duvuru Geetha; Karina A Keogh; Eugene Y Kissin; Paul A Monach; Tobias Peikert; Coen Stegeman; Steven R Ytterberg; Ulrich Specks
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

3.  Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

Authors:  Rachel B Jones; Jan Willem Cohen Tervaert; Thomas Hauser; Raashid Luqmani; Matthew D Morgan; Chen Au Peh; Caroline O Savage; Mårten Segelmark; Vladimir Tesar; Pieter van Paassen; Dorothy Walsh; Michael Walsh; Kerstin Westman; David R W Jayne
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

4.  Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center.

Authors:  Rodrigo Cartin-Ceba; Jason M Golbin; Karina A Keogh; Tobias Peikert; Marta Sánchez-Menéndez; Steven R Ytterberg; Fernando C Fervenza; Ulrich Specks
Journal:  Arthritis Rheum       Date:  2012-11

5.  Wegener's granulomatosis: clinical course in 108 patients with renal involvement.

Authors:  K Aasarød; B M Iversen; J Hammerstrøm; L Bostad; L Vatten; S Jørstad
Journal:  Nephrol Dial Transplant       Date:  2000-05       Impact factor: 5.992

Review 6.  Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study.

Authors:  Anthony D Booth; Mike K Almond; Aine Burns; Peter Ellis; Gill Gaskin; Guy H Neild; Martin Plaisance; Charles D Pusey; David R W Jayne
Journal:  Am J Kidney Dis       Date:  2003-04       Impact factor: 8.860

7.  Outcome of ANCA-associated primary renal vasculitis in Miyazaki Prefecture.

Authors:  Shigehiro Uezono; Yuji Sato; Seiichiro Hara; Shuichi Hisanaga; Keiichi Fukudome; Shouichi Fujimoto; Hiroyuki Nakao; Kazuo Kitamura; Shigeto Kobayashi; Kazuo Suzuki; Hiroshi Hashimoto; Hiroyuki Nunoi
Journal:  Intern Med       Date:  2007-06-15       Impact factor: 1.271

8.  Clinical trial for Japanese patients with myeloperoxidase anti-neutrophil cytoplasmic antibody-associated vasculitis: the JMAAV study.

Authors:  Shoichi Ozaki
Journal:  Clin Exp Nephrol       Date:  2013-06-19       Impact factor: 2.801

9.  Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients.

Authors:  C Charlier; C Henegar; O Launay; C Pagnoux; A Berezné; B Bienvenu; P Cohen; L Mouthon; L Guillevin
Journal:  Ann Rheum Dis       Date:  2008-05-26       Impact factor: 19.103

10.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.

Authors:  J C Jennette; R J Falk; P A Bacon; N Basu; M C Cid; F Ferrario; L F Flores-Suarez; W L Gross; L Guillevin; E C Hagen; G S Hoffman; D R Jayne; C G M Kallenberg; P Lamprecht; C A Langford; R A Luqmani; A D Mahr; E L Matteson; P A Merkel; S Ozen; C D Pusey; N Rasmussen; A J Rees; D G I Scott; U Specks; J H Stone; K Takahashi; R A Watts
Journal:  Arthritis Rheum       Date:  2013-01
View more
  5 in total

Review 1.  Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica.

Authors:  Dario Camellino; Eric L Matteson; Frank Buttgereit; Christian Dejaco
Journal:  Nat Rev Rheumatol       Date:  2020-08-05       Impact factor: 20.543

2.  Infectious profile in inpatients with ANCA-associated vasculitis: a single-center retrospective study from Southern China.

Authors:  Minxi Lao; Mingcheng Huang; Chen Li; Hao Li; Qian Qiu; Zhongping Zhan; Dongying Chen
Journal:  Clin Rheumatol       Date:  2019-10-02       Impact factor: 2.980

3.  Invasive mycoses in patients with connective tissue disease from Southern China: clinical features and associated factors.

Authors:  Minxi Lao; Zhongping Zhan; Fan Su; Hao Li; Zheng Yang; Haihong Chen; Liuqin Liang; Dongying Chen
Journal:  Arthritis Res Ther       Date:  2019-03-11       Impact factor: 5.156

4.  Association between body mass index and severe infection in older adults with microscopic polyangiitis: a retrospective cohort in Japan.

Authors:  Hirokazu Sugiyama; Makoto Yamaguchi; Takayuki Katsuno; Shiho Iwagaitsu; Hironobu Nobata; Hiroshi Kinashi; Shogo Banno; Masahiko Ando; Yoko Kubo; Takuji Ishimoto; Yasuhiko Ito
Journal:  BMC Geriatr       Date:  2021-03-09       Impact factor: 3.921

5.  Initial high-dose corticosteroids and renal impairment are risk factors for early severe infections in elderly patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: A retrospective observational study.

Authors:  Daisuke Waki; Keisuke Nishimura; Hironobu Tokumasu; Keiichiro Kadoba; Hiroki Mukoyama; Rintaro Saito; Hiroyuki Murabe; Toshihiko Yokota
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.